Study to evaluate safety and immunogenicity of a pandemic flu H5 mRNA vaccine in healthy adults aged 18 years and older

Trial Identifier: VBS00001
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: December 2024
Primary Completion Date: March 2026
Study Completion Date: March 2026
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
UNITED STATES, California LA MESA, California, UNITED STATES, 91942
UNITED STATES, Florida DELAND, Florida, UNITED STATES, 32720
UNITED STATES, Florida Lakeland, Florida, UNITED STATES, 33803
UNITED STATES, Florida LARGO, Florida, UNITED STATES, 33777
UNITED STATES, Georgia ATLANTA, Georgia, UNITED STATES, 30342
UNITED STATES, Georgia DECATUR, Georgia, UNITED STATES, 30030-2627
UNITED STATES, Michigan BINGHAM FARMS, Michigan, UNITED STATES, 48334
UNITED STATES, Nebraska NORFOLK, Nebraska, UNITED STATES, 68701
UNITED STATES, Nebraska OMAHA, Nebraska, UNITED STATES, 68134
UNITED STATES, Ohio CINCINNATI, Ohio, UNITED STATES, 45246
UNITED STATES, South Carolina NORTH CHARLESTON, South Carolina, UNITED STATES, 29405
UNITED STATES, Texas SUGAR LAND, Texas, UNITED STATES, 77479
UNITED STATES, Utah WEST JORDAN, Utah, UNITED STATES, 84088
UNITED STATES, Virginia CHARLOTTESVILLE, Virginia, UNITED STATES, 22911